Long-Term Care of the Liver Transplant Recipient

Clinics in Liver Disease

Volumn 11, Issue 2, 2007, Pages 397-416

  Liu, Lawrence U ^a   Schiano, Thomas D ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ALENDRONIC ACID; AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; ATORVASTATIN; AZATHIOPRINE; BASILIXIMAB; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCINEURIN INHIBITOR; CORTICOSTEROID DERIVATIVE; CYCLOSPORIN; DACLIZUMAB; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; LISINOPRIL; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OKT 3; PIOGLITAZONE; PREDNISONE; RAPAMYCIN; ROSIGLITAZONE; SPIRONOLACTONE; STEROID; SULFONYLUREA; TACROLIMUS; TETRAHYDROLIPSTATIN; THIAZIDE DIURETIC AGENT; THYMOCYTE ANTIBODY; UNINDEXED DRUG;

ABDOMINAL PAIN; AKINETIC MUTISM; ALOPECIA; AMENORRHEA; ANEMIA; ANOREXIA; ARTERY THROMBOSIS; ASEPTIC MENINGITIS; ATAXIC APHASIA; AVASCULAR NECROSIS; BONE MARROW SUPPRESSION; BONE MASS; BONE TURNOVER; BRONCHIOLITIS OBLITERANS ORGANIZING PNEUMONIA; CANCER; CARDIOVASCULAR DISEASE; CHOLESTASIS; COLON PERFORATION; COMBINATION CHEMOTHERAPY; CONVULSION; DEPRESSION; DIABETES MELLITUS; DIARRHEA; DYSLIPIDEMIA; ELECTROLYTE DISTURBANCE; ESOPHAGITIS; EUPHORIA; FEMALE SUBFERTILITY; FEVER; GASTROINTESTINAL TOXICITY; GINGIVA HYPERPLASIA; GRAFT REJECTION; GROWTH RETARDATION; HEADACHE; HEARING IMPAIRMENT; HEART DISEASE; HEMOLYTIC UREMIC SYNDROME; HEPATITIS; HEPATITIS C; HIRSUTISM; HUMAN; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; HYPERKALEMIA; HYPERLIPIDEMIA; HYPERSENSITIVITY REACTION; HYPERTENSION; HYPERTRIGLYCERIDEMIA; HYPOMAGNESEMIA; INFECTION; INSOMNIA; INTERSTITIAL PNEUMONIA; KIDNEY DYSFUNCTION; LEUKOPENIA; LIVER CIRRHOSIS; LIVER DISEASE; LIVER GRAFT; LIVER TOXICITY; LONG TERM CARE; MACROCYTIC ANEMIA; MALIGNANT NEOPLASTIC DISEASE; MOUTH ULCER; MYALGIA; MYOSITIS; NAUSEA; NAUSEA AND VOMITING; NEPHROTOXICITY; NEUROTOXICITY; NEUTROPENIA; NONHUMAN; OBESITY; OSTEOPENIA; OSTEOPOROSIS; PANCREATITIS; PANCYTOPENIA; PATHOPHYSIOLOGY; PERIPHERAL NEUROPATHY; PLEURA EFFUSION; PREECLAMPSIA; PREVALENCE; RECIPIENT; REVIEW; SIDE EFFECT; STEATORRHEA; STOMACH ULCER; SURVIVAL RATE; T CELL DEPLETION; THROMBOCYTOPENIA; TREMOR; VEIN OCCLUSION; VOMITING; WEIGHT GAIN; WOUND HEALING IMPAIRMENT;

CARDIOVASCULAR DISEASES; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LIVER DISEASES; LIVER TRANSPLANTATION; LONG-TERM CARE; METABOLIC DISEASES; PREGNANCY; PREGNANCY COMPLICATIONS;

EID: 34250841946     PISSN: 10893261     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cld.2007.04.003     Document Type: Review

References (167)

1. Stegall M.D., Everson G., Schroter G., et al. Metabolic complications after liver transplantation. Diabetes, hypercholesterolemia, hypertension, and obesity. Transplantation 60 9 (1995) 1057-1060
2. Reuben A. Long-term management of the liver transplant patient: diabetes, hyperlipidemia, and obesity. Liver Transpl 7 11 Suppl 1 (2001) S13-S21
3. Rabkin J.M., de La Melena V., Orloff S.L., et al. Late mortality after orthotopic liver transplantation. Am J Surg 181 5 (2001) 475-479
4. Asfar S., Metrakos P., Fryer J., et al. An analysis of late deaths after liver transplantation. Transplantation 61 9 (1996) 1377-1381
5. Kingston M.E., Ashcraft M., Atiyeh M., et al. Diabetes mellitus in chronic active hepatitis and cirrhosis. Gastroenterology 87 3 (1984) 688-694
6. Collins J.R., Lacy W.W., Stiel J.N., et al. Glucose intolerance and insulin resistance in patients with liver disease. Arch Intern Med 126 4 (1970) 608-614
7. Mason A.L., Lau J.Y., Hoang N., et al. Association of diabetes mellitus and chronic hepatitis C virus infection. Hepatology 29 2 (1999) 328-333
8. Caronia S., Taylor K., Pagliaro L., et al. Further evidence for an association between non-insulin-dependent diabetes mellitus and chronic hepatitis C virus infection. Hepatology 30 4 (1999) 1059-1063
9. Allison M.E., Wreghitt T., Palmer C.R., et al. Evidence for a link between hepatitis C virus infection and diabetes mellitus in a cirrhotic population. J Hepatol 21 6 (1994) 1135-1139
10. Lecube A., Hernandez C., Genesca J., et al. High prevalence of glucose abnormalities in patients with hepatitis C virus infection: a multivariate analysis considering the liver injury. Diabetes Care 27 5 (2004) 1171-1175
11. Nolte W., Hartmann H., and Ramadori G. Glucose metabolism and liver cirrhosis. Exp Clin Endocrinol Diabetes 103 2 (1995) 63-74
12. Letiexhe M.R., Scheen A.J., Gerard P.L., et al. Insulin secretion, clearance, and action on glucose metabolism in cirrhotic patients. J Clin Endocrinol Metab 77 5 (1993) 1263-1268
13. Baid S., Cosimi A.B., Farrell M.L., et al. Posttransplant diabetes mellitus in liver transplant recipients: risk factors, temporal relationship with hepatitis C virus allograft hepatitis, and impact on mortality. Tranpslantation 72 6 (2001) 1066-1072
14. Blanco J.J., Herrero J.I., Quiroga J., et al. Liver transplantation in cirrhotic patients with diabetes mellitus: midterm results, survival, and adverse events. Liver Transpl 7 3 (2001) 226-233
15. Zein N.N., Abdulkarim A.S., Wiesner R.H., et al. Prevalence of diabetes mellitus inpatients with end-stage liver cirrhosis due to hepatitis C, alcohol, or cholestatic disease. J Hepatol 32 2 (2000) 209-217
16. Yoo H.Y., and Thuluvath P.J. The effect of insulin-dependent diabetes mellitus on outcome of liver transplantation. Transplantation 74 7 (2002) 1007-1012
17. Krentz A.J., Dmitrewski J., Mayer D., et al. Postoperative glucose metabolism in liver transplant recipients: a two-year prospective randomized study of cyclosporine versus FK506. Tranpslantation 57 11 (1994) 1666-1669
18. Navasa M., Bustamante J., Marroni C., et al. Diabetes mellitus after liver transplantation: prevalence and predictive factors. J Hepatol 25 1 (1996) 64-71
19. AlDosary A.A., Ramji A.S., Elliott T.G., et al. Post-liver transplantation diabetes mellitus: an association with hepatitis C. Liver Transpl 8 4 (2002) 356-361
20. Saab S., Shpaner A., Zhao Y., et al. Prevalence and risk factors for diabetes mellitus in moderate term survivors of liver transplantation. Am J Transplant 6 8 (2006) 1890-1895
21. John P.R., and Thuluvath P.J. Outcome of patients with new-onset diabetes mellitus after liver transplantation compared with those without diabetes mellitus. Liver Transpl 8 8 (2002) 708-713
22. Trail K.C., Stratta R.J., Larsen J.L., et al. Results of liver transplantation in diabetic recipients. Surgery 114 4 (1993) 650-656
23. John P.R., and Thuluvath P.J. Outcome of liver transplantation in patients with diabetes mellitus: a case-control study. Hepatology 34 5 (2001) 889-895
24. Davidson J., Wilkinson A., Dantal J., et al. New-onset diabetes after transplantation: 2003 international consensus guidelines. Transplantation 75 10 Suppl (2003) S3-S24
25. Trail K.C., McCashland T.M., Larsen J.L., et al. Morbidity in patients with posttransplant diabetes mellitus following orthotopic liver transplantation. Liver Transpl Surg 2 4 (1996) 276-283
26. Steinmuller T.H., Stockmann M., Bechstein W.O., et al. Liver transplantation and diabetes mellitus. Exp Clin Endocrinol Diabetes 108 6 (2000) 401-405
27. Wahlstrom H.E., Cooper J., Gores G., et al. Survival after liver transplantation in diabetics. Transplant Proc 23 1 Pt 2 (1991) 1565-1566
28. Khalili M., Lim J.W., Bass N., et al. New onset diabetes mellitus after liver transplantation: the critical role of hepatitis C infection. Liver Transpl 10 3 (2004) 349-355
29. Marroni C.A., Hoppe L., Diehl J.L., et al. Diabetes mellitus and liver transplantation in adults. Transplant Proc 31 7 (1999) 3046
30. Ericzon B., Groth C., Bismuth H., et al. Glucose metabolism in liver transplant recipients treated with FK 506 or cyclosporine in the European multicentre study. Transpl Int 7 Suppl 1 (1994) S11-S14
31. Tueche S.G. Diabetes mellitus after liver transplant new etiologic clues and cornerstones for understanding. Transplant Proc 35 4 (2003) 1466-1468
32. Mora P.F. Post-transplantation diabetes mellitus. Am J Med Sci 329 2 (2005) 86-94
33. Foxton M.R., Quaglia A., Muiesan P., et al. The impact of diabetes mellitus on fibrosis progression in patients transplanted for hepatitis C. Am J Transplant 6 8 (2006) 1922-1929
34. Krentz A.J., Dousset B., Mayer D., et al. Metabolic effects of cyclosporine A and FK506 in liver transplant recipients. Diabetes 42 12 (1993) 1753-1759
35. US Multicentre FK506 Liver Study Group. A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression in liver transplantation. N Engl J Med 331 17 (1994) 1110-1115
36. Rilo H.L., Zeng Y., Alejandro R., et al. Effect of FK506 on human islets of Langerhans. Transplant Proc 23 6 (1991) 3164-3165
37. Shields P.L., Tang H., Neuberger J.M., et al. Poor outcome in patients with diabetes mellitus undergoing liver transplantation. Transplantation 68 4 (1999) 530-535
38. Soule J.L., Olyaei A.J., Boslaugh T.A., et al. Hepatitis C infection increases the risk of new-onset diabetes after transplantation in liver allograft recipients. Am J Surg 189 5 (2005) 522-527
39. Bigam D.L., Pennington J.J., Carpentier A., et al. Hepatitis C-related cirrhosis: a predictor of diabetes after liver transplantation. Hepatology 32 1 (2000) 87-90
40. Salvadori M., Bertoni E., Rosati A., et al. Post-transplant diabetes mellitus. J Nephrol 16 5 (2003) 626-634
41. Villanueva G., and Baldwin D. Rosiglitazone therapy of posttransplant diabetes mellitus. Transplantation 80 10 (2005) 1402-1405
42. Baldwin Jr. D., and Duffin K.E. Rosiglitazone treatment of diabetes mellitus after solid organ transplantation. Transplantation 77 7 (2004) 1009-1014
43. Luther P., and Baldwin Jr. D. Pioglitazone in the management of diabetes mellitus after transplantation. Am J Transplant 4 12 (2004) 2135-2138
44. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352 9131 (1998) 837-853
45. Plotkin J.S., Scott V.L., Pinna A., et al. Morbidity and mortality in patients with coronary artery disease undergoing orthotopic liver transplantation. Liver Transpl Surg 2 6 (1996) 426-430
46. Johnston S.D., Morris J.K., Cramb R., et al. Cardiovascular morbidity and mortality after orthotopic liver transplantation. Transplantation 73 6 (2002) 901-906
47. Donovan C.L., Marcovitz P.A., Punch J.D., et al. Two-dimensional and dobutamine stress echocardiography in the preoperative assessment of patients with end-stage liver disease prior to orthotopic liver transplantation. Transplantation 61 8 (1996) 1180-1188
48. Williams K., Lewis J.F., Davis G., et al. Dobutamine stress echocardiography in patients undergoing liver transplantation evaluation. Transplantation 69 11 (2000) 2354-2356
49. Neal D.A., Tom B.D., Luan J., et al. Is there disparity between risk and incidence of cardiovascular disease after liver transplant?. Transplantation 77 1 (2004) 93-99
50. Muñoz S.J., and ElGenaidi H. Cardiovascular risk factors after liver transplantation. Liver Transpl 11 11 Suppl 1 (2005) S52-S56
51. Rabkin J., Corless C., Rosen H., et al. Immunosuppression impact on long-term cardiovascular complications after liver transplantation. Am J Surg 183 5 (2002) 595-599
52. Neal D.A., Gimson A.E., Gibbs P., et al. Beneficial effects of converting liver transplant recipients from cyclosporine to tacrolimus on blood pressure, serum lipids, and weight. Liver Transpl 7 6 (2001) 533-539
53. Dikow R., Degenhard M., Kraus T., et al. Blood pressure profile and treatment quality in liver allograft recipients-benefit of tacrolimus versus cyclosporine. Transplant Proc 36 5 (2004) 1512-1515
54. Kobashigawa J.A., and Kasiske B.L. Hyperlipidemia in solid organ transplantation. Transplantation 63 3 (1997) 331-338
55. Palombo J.D., Lopes S.M., Zeisel S.H., et al. Effectiveness of orthotopic liver transplantation on the restoration of cholesterol metabolism in patients with end-stage liver disease. Gastroenterology 93 6 (1987) 1170-1177
56. Trotter J.F., Wachs M., Bak T., et al. Liver transplantation using sirolimus and minimal corticosteroids (3-day taper). Transplantation 7 4 (2001) 343-351
57. Steinmüller T.M., Gräf K.J., Schleicher J., et al. The effect of FK 506 vs. cyclosporine on glucose and lipid metabolism - a randomized trial. Transplantation 58 6 (1994) 669-674
58. Kahan B.D. Sirolimus: a new agent for clinical renal transplantation. Transplant Proc 29 1-2 (1997) 48-50
59. Murgia M.G., Jordan S., and Kahan B.D. The side effect profile of sirolimus: a phase I study in quiescent cyclosporine-prednisone-treated renal transplant patients. Kidney Int 49 1 (1996) 209-216
60. MacDonald A.S., and RAPAMUNE Global Study Group. A world-wide, phase III, randomized, controlled, safety and efficacy study of a sirolimus/cyclosporine regimen for prevention of acute rejection in recipients of primary mismatched renal allografts. Transplantation 71 2 (2001) 271-280
61. Keane W.F. Lipids and progressive renal disease: the cardio-renal link. Am J Kidney Dis 34 2 (1999) xliii-xlvi
62. Morrissett J.D., Abdel-Fattah G., Hoogeveen R., et al. Effect of sirolimus on plasma lipids and lipoprotein levels in renal transplant patients. Transplantation 67 Suppl (1999) S60
63. Trotter J.F., Wachs M.E., Trouillot T.E., et al. Dyslipidemia during sirolimus therapy in liver transplant recipients occurs with concomitant cyclosporine but not tacrolimus. Liver Transpl 7 5 (2001) 401-408
64. Watson C.J., Friend P.J., Jamieson N.V., et al. Sirolimus: a potent new immunosuppressant for liver transplantation. Transplantation 67 4 (1999) 505-509
65. McAlister V.C., Peltekian K.M., Malatjalian D.A., et al. Orthotopic liver transplantation using low-dose tacrolimus and sirolimus. Liver Transpl 7 8 (2001) 701-708
66. Kniepeiss D., Iberer F., Schaffellner S., et al. Dyslipidemia during sirolimus therapy in patients after liver transplantation. Clin Transplant 18 6 (2004) 642-646
67. Pratschke J., Neuhaus R., Tullius S.G., et al. Treatment of cyclosporine-related adverse effects by conversion to tacrolimus after liver transplantation. Transplantation 64 6 (1997) 938-940
68. Manzarbeitia C., Reich D.J., Rothstein K.D., et al. Tacrolimus conversion improves hyperlipidemic states in stable liver transplant recipients. Liver Transpl 7 2 (2001) 93-99
69. Roy A., Kneteman N., Lilly L., et al. Tacrolimus as intervention in the treatment of hyperlipidemia after liver transplant. Transplantation 82 4 (2006) 494-500
70. Grundy S., Cleeman J., Bairey N., et al. Implications of recent clinical trials for the national Cholesterol Education program adult treatment panel III guidelines. Circulation 110 2 (2004) 227-239
71. Gazi I.F., Liberopoulos E.N., Athyros V.G., et al. Statins and solid organ transplantation. Curr Pharm Des 12 36 (2006) 4771-4783
72. Holdaas H., Fellstrom B., and Jardine A. Clinical practice guidelines for managing dyslipidemias in kidney transplant patients: lessons to be learnt from the assessment of Lescol in renal transplantation (ALERT) trial. Am J Transplant 5 6 (2005) 1574-1575
73. Taylor P.J., Kubler P.A., Lynch S.V., et al. Effect of atorvastatin on cyclosporine pharmacokinetics in liver transplant recipients. Ann Pharmacother 38 2 (2003) 205-208
74. Katznelson S. Effect of HMG-CoA reductase inhibitors on chronic allograft rejection. Kidney Int Suppl 71 (1999) S117-S121
75. Rouillard S., and Lane N.E. Hepatic osteodystrophy. Hepatology 33 1 (2001) 301-307
76. Collier J.D., and Ninkovic M. Guidelines on the management of osteoporosis associated with chronic liver disease. Gut 50 Suppl 1 (2002) 1-19
77. Leslie W.D., Bernstein C.N., and Leboff M.S. American Gastroenterological Association Clinical Practice Committee. AGA technical review on osteoporosis in hepatic disorders. Gastroenterology 125 3 (2003) 941-966
78. Haagsma E.B., Thijn C.J., Post J.G., et al. Bone disease after orthotopic liver transplantation. J Hepatol 6 1 (1988) 94-100
79. Ninkovic M., Skingle S.J., Bearcroft P.W., et al. Incidence of vertebral fractures in the first three months after orthotopic liver transplantation. Eur J Gastroenterol Hepatol 12 8 (2000) 931-935
80. Ninkovic M., Love S., Tom B.D., et al. Lack of effect of intravenous pamidronate on fracture incidence and bone mineral density after orthotopic liver transplantation. J Hepatol 37 1 (2002) 93-100
81. Compston J.E. Osteoporosis after liver transplantation. Liver Transpl 9 4 (2003) 321-330
82. Lichtenstein G.R., Sands B.E., and Pazianas M. Prevention and treatment of osteoporosis in inflammatory bowel disease. Inflamm Bowel Dis 12 8 (2006) 797-813
83. Sambrook P., Birmingham J., Kempler S., et al. Corticosteroid effects on proximal femur bone loss. J Bone Miner Res 5 12 (1990) 1211-1216
84. Van Staa T., Leufkens H.G., Abenhaim L., et al. Use of oral corticosteroids and risk of fractures. J Bone Miner Res 15 6 (2000) 993-1000
85. Diaz-Guerra G.M., Gomez R., Jodar E., et al. Long-term follow-up of bone mass after orthotopic liver transplantation: effect of steroid withdrawal from the immunosuppressive regimen. Osteoporos Int 13 (2002) 147-150
86. Cvetkovic M., Mann G.N., Roomero D.F., et al. The deleterious effects of long-term cyclosporine A, cyclosporine G, and FK506 on bone mineral metabolism in vivo. Transplantation 57 8 (1994) 1231-1237
87. Romero D.F., Buchinsky F.J., Rucinski B., et al. Rapamycin: a bone sparing immunosuppressant?. J Bone Miner Res 10 5 (1995) 760-768
88. Millonig G., Graziadei I.W., Eichler D., et al. Alendronate in combination with calcium and vitamin D prevents bone loss after orthotopic liver transplantation: a prospective single-center study. Liver Transpl 11 8 (2005) 960-966
89. Pennisi P., Trombetti A., Giostra E., et al. Pamidronate and osteoporosis prevention in liver transplant recipients. Rheumatol Int 27 3 (2006) 251-256
90. Sanchez A.J., and Aranda-Michel J. Liver disease and osteoporosis. Nutr Clin Pract 21 3 (2006) 273-278
91. Seo S, Maganti K, Khehra M, et al. De novo nonalcoholic fatty liver disease after liver transplantation. Liver Transpl, in press.
92. Yamamoto K., Takada Y., Fujimoto Y., et al. Nonalcoholic steatohepatitis in donors for living donor liver transplantation. Transplantation 83 3 (2007) 257-262
93. Cassiman D., Roelants M., Vandenplas G., et al. Orlistat treatment is safe in overweight and obese liver transplant recipients: a prospective, open label trial. Transpl Int 19 12 (2006) 1000-1005
94. Porayko M.K., Gonwa T.A., Klintmalm G.B., et al. Comparing nephrotoxicity of FK 506 and cyclosporine regimens after liver transplantation: preliminary results from US Multicenter trial. Transplant Proc 27 1 (1995) 1114-1116
95. Brown Jr. R.S., Lombardero M., and Lake J.R. Outcome of patients with renal insufficiency undergoing liver or liver-kidney transplantation. Transplantation 62 12 (1996) 1788-1793
96. Gonwa T.A., Morris C.A., Goldstein R.M., et al. Long-term survival and renal function following liver transplantation in patients with and without hepatorenal syndrome: experience in 300 patients. Transplantation 51 2 (1991) 428-430
97. Bennett W.M. Insights into chronic cyclosporine nephrotoxicity. Int J Clin Pharmacol Ther 34 11 (1996) 515-519
98. Guitard J., Ribes D., Kamar N., et al. Predictive factors for chronic renal failure one year after orthotopic liver transplantation. Ren Fail 28 5 (2006) 419-425
99. Weir M.R., and Fink J.C. Risk for posttransplant diabetes mellitus with current immunosuppressive medications. Am J Kidney Dis 34 1 (1999) 1-13
100. Pawarode A., Fine D.M., and Thuluvath P.J. Independent risk factors and natural history of renal dysfunction in liver transplant recipients. Liver Transpl 9 7 (2003) 741-747
101. Cohen A.J., Stegall M.D., Rosen C.B., et al. Chronic renal dysfunction late after liver transplantation. Liver Transpl 8 10 (2002) 916-921
102. Gonwa T.A., Mai M.L., Melton L.B., et al. End-stage renal disease (ESRD) after orthotopic liver transplantation (OLTX) using calcineurin-based immunotherapy: risk of development and treatment. Transplantation 72 12 (2001) 1934-1939
103. Nair S., Verma S., and Thuluvath P.J. Pretransplant renal function predicts survival in patients undergoing orthotopic liver transplantation. Hepatology 35 5 (2002) 1179-1185
104. Bilbao I., Charco R., Balsells J., et al. Risk factors for acute renal failure requiring dialysis after liver transplantation. Clin Transplant 12 2 (1998) 123-129
105. Singh N., Gayowski T., and Wagener M.M. Posttransplant dialysis-associated morbidity and impact on outcome in liver transplant recipients. Liver Transpl 7 2 (2001) 100-105
106. Fisher N.C., Nightingale P.G., Gunson B.K., et al. Chronic renal failure following liver transplantation. Transplantation 66 1 (1998) 59-66
107. Lafayette R.A., Pare G., Schmid C.H., et al. Pretransplant renal dysfunction predicts poorer outcome in liver transplantation. Clin Nephrol 48 3 (1997) 159-164
108. Campbell M.S., Kotlyar D.S., Brensinger C.M., et al. Renal function after orthotopic liver transplantation is predicted by duration of pretransplantation creatinine elevation. Liver Transpl 11 9 (2005) 1048-1055
109. Ojo A.O., Held P.J., Port F.K., et al. Chronic renal failure after transplantation of a nonrenal organ. N Engl J Med 349 10 (2003) 931-940
110. Gabardi S., and Luu L. Nonprescription analgesics and their use in solid-organ transplantation: a review. Prog Transplant 14 3 (2004) 182-190
111. O'Riordan A., Wong V., McCormick A., et al. Chronic kidney disease post-liver transplantation. Nephrol Dial Transplant 21 9 (2006) 2630-2636
112. Morard I., Mentha G., Spahr L., et al. Long-term renal function after liver transplantation is related to calcineurin inhibitors blood levels. Clin Transplant 20 1 (2005) 96-101
113. Raimundo M.L., Dagher L., Papatheodoridis G.V., et al. Long-term mycophenolate mofetil monotherapy in combination with calcineurin inhibitors for chronic renal dysfunction after liver transplantation. Transplantation 75 2 (2003) 186-190
114. Reich D.J., Clavien P.A., Hodge E.E., and MMF Renal Dysfunction after Liver Transplantation Working Group. Mycophenolate mofetil for renal dysfunction in liver transplant recipients on cyclosporine or tacrolimus: randomized, prospective, multicenter pilot study results. Transplantation 80 1 (2005) 18-25
115. Johnson R.W., Kreis H., Oberbauer R., et al. Sirolimus allows early cyclosporine withdrawal in renal transplantation resulting in improved renal function and lower blood pressure. Transplantation 72 5 (2001) 777-786
116. Fairbanks K.D., Eustace J.A., Fine D., et al. Renal function improves in liver transplant recipients when switched from a calcineurin inhibitor to sirolimus. Liver Transpl 9 10 (2003) 1079-1085
117. Nair S., Eason J., and Loss G. Sirolimus monotherapy in nephrotoxicity due to calcineurin inhibitors in liver transplant recipients. Liver Transpl 9 2 (2003) 126-129
118. Kniepeiss D., Iberer F., Schaffellner S., et al. Nonnephrotoxic immunosuppression in patients after liver transplantation. Int Immunopharmacol 5 1 (2005) 133-136
119. Sanchez E.Q., Martin A.P., Ikegami T., et al. Sirolimus conversion after liver transplantation: improvement in measured glomerular filtration rate after 2 years. Transplant Proc 37 10 (2005) 4416-4423
120. Christopher V., Al-Chalabi T., Richardson P.D., et al. Pregnancy outcome after liver transplantation: a single-center experience of 71 pregnancies in 45 recipients. Liver Transpl 12 7 (2006) 1138-1143
121. Cundy T.F., O'Grady J.G., and Williams R. Recovery of menstruation and pregnancy after liver transplantation. Gut 31 3 (1990) 337-338
122. Riely C.A. Contraception and pregnancy after liver transplantation. Liver Transpl 7 11 Suppl 1 (2001) S74-S76
123. Brown K.A., and Lucey M.R. Liver transplantation restores female reproductive endocrine function. Hepatology 13 6 (1991) 1255-1257
124. Haagsma E.B., Visser G.H., Klompmaker I.J., et al. Successful pregnancy after orthotopic liver transplantation. Obstet Gynecol 74 3 Pt 2 (1989) 442-443
125. Venkataramanan R., Koneru B., Wang C.C., et al. Cyclosporine and its metabolites in mother and baby. Transplantation 46 3 (1988) 468-469
126. Scantlebury V., Gordon R., Tzakis A., et al. Childbearing after liver transplantation. Transplantation 49 2 (1990) 317-321
127. Patapis P., Irani S., Mirza D.F., et al. Outcome of graft function and pregnancy following liver transplantation. Transplant Proc 29 1-2 (1997) 1565-1566
128. Jain A.B., Reyes J., Marcos A., et al. Pregnancy after liver transplantation with tacrolimus immunosuppression: a single center's experience update after 13 years. Transplantation 76 5 (2003) 827-832
129. Dei Malatesta M.F., Rossi M., Rocca B., et al. Pregnancy after liver transplantation: report of 8 new cases and review of the literature. Transpl Immunol 15 4 (2006) 297-302
130. Arsan A., Guest G., Gagnadoux M.F., et al. Pregnancy in renal transplantation: a pediatric unit report. Transplant Proc 29 5 (1997) 2479
131. Pahl M.V., Vaziri N.D., Kaufman D.J., et al. Childbirth after renal transplantation. Transplant Proc 25 4 (1993) 2727-2731
132. Coulam C.B., Moyer T.P., Jiang N.S., et al. Breast-feeding after renal transplantation. Transplant Proc 14 3 (1982) 605-609
133. Flechner S.M., Katz A.R., Rogers A.J., et al. The presence of cyclosporine in body tissues and fluids during pregnancy. Am J Kidney Dis 5 1 (1985) 60-63
134. American Academy of Pediatrics Committee on Drugs. The transfer of drugs and other chemicals into human milk. Pediatrics 108 3 (2001) 776-789
135. EBPG Expert Group on Renal Transplantation. European best practice guidelines for renal transplantation. Section IV: long-term management of the transplant recipient. IV.10. pregnancy in renal transplant recipients. Nephrol Dial Transplant 17 Suppl 4 (2002) 50-55
136. Hou S. Pregnancy in chronic renal insufficiency and end stage liver disease. Am J Kidney Dis 33 2 (1999) 235-252
137. Kainz A., Harabacz I., Cowlrick I.S., et al. Review of the course and outcome of 100 pregnancies in 84 women treated with tacrolimus. Transplantation 70 12 (2000) 1718-1721
138. Nagy S., Bush M.C., Berkowitz R., et al. Pregnancy outcome in liver transplant recipients. Obstet Gynecol 102 1 (2003) 121-128
139. Ostensen M. Disease specific problems related to drug therapy in pregnancy. Lupus 13 9 (2004) 746-750
140. Blanford A.T., and Murphy B.E. In vitro metabolism of prednisolone, dexamethasone, betamethasone, and cortisol by the human placenta. Am J Obstet Gynecol 127 3 (1977) 264-267
141. Shaheen F.A., al-Sulaiman M.H., and al-Khader A.A. Long-term nephrotoxicity after exposure to cyclosporine in utero. Transplantation 56 1 (1993) 244-245
142. Ferrero S., and Ragni N. Inflammatory bowel disease: management issues during pregnancy. Arch Gynecol Obstet 270 2 (2004) 79-85
143. Ho J.K., Ko H.H., Schaeffer D.F., et al. Sexual health after orthotopic liver transplantation. Liver Transpl 12 10 (2006) 1478-1484
144. Gomez-Lobo V., Burgansky A., Kim-Schluger L., et al. Gynecologic symptoms and sexual function before and after liver transplantation. J Reprod Med 51 6 (2006) 457-462
145. Sorrell J.H., and Brown J.R. Sexual functioning in patients with end-stage liver disease before and after transplantation. Liver Transpl 12 10 (2006) 1473-1477
146. Yao F.Y., Gautam M., Palese C., et al. De novo malignancies following liver transplantation: a case-control study with long-term follow-up. Clin Transplant 20 5 (2006) 617-623
147. Vallejo G.H., Romero C.J., and de Vicente J.C. Incidence and risk factors for cancer after liver transplantation. Crit Rev Oncol Hematol 56 1 (2005) 87-99
148. Benlloch S., Berenguer M., Prieto M., et al. De novo internal neoplasms after liver transplantation: increased risk and aggressive behavior in recent years?. Am J Transplant 4 4 (2004) 596-604
149. Herrero J.I., Lorenzo M., Quiroga J., et al. De novo neoplasia after liver transplantation: an analysis of risk factors and influence on survival. Liver Transpl 11 1 (2005) 89-97
150. Fung J.J., Jain A., Kwak E.J., et al. De novo malignancies after liver transplantation: a major cause of late death. Liver Transpl 7 Suppl 1 (2001) S109-S118
151. Pruthi J., Medkiff K.A., Esrason K.T., et al. Analysis of causes of death in liver transplant recipients who survived more than 3 years. Liver Transpl 7 9 (2001) 811-815
152. Kauffman H.M., Cherikh W.S., and Cheng Y. Posttransplantation malignancies: a problem, a challenge, and an opportunity. Liver Transpl 8 5 (2002) 488-490
153. Sheil A.G.R. Malignancy following liver transplantation: a report from the Australian Combined Liver Transplant Registry. Transplant Proc 27 1 (1995) 1247
154. Jain A.B., Yee L.D., Nalesnik M.A., et al. Comparative incidence of de novo nonlymphoid malignancies after liver transplantation under tacrolimus using Surveillance Epidemiologic End Results data. Transplantation 66 9 (1998) 1193-1200
155. Jain A., DiMartini A., Kashyap R., et al. Long-term follow-up after liver transplantation for alcoholic liver disease under tacrolimus. Transplantation 70 9 (2000) 1335-1342
156. Levy M., Backman L., Husberg B., et al. De novo malignancy following liver transplantation: a single center study. Transplant Proc 25 1 Pt 2 (1993) 1397-1399
157. Sheiner P.A., Magliocca J.F., Bodian C.A., et al. Long-term medical complications in patients surviving > 5 years after liver transplantation. Transplantation 69 5 (2000) 781-789
158. Sanchez E.Q., Marubashi S., Jung G., et al. De novo tumors after liver transplantation: a single-institution experience. Liver Transpl 8 3 (2002) 285-291
159. Herrero J.I., Lucena J.F., Quiroga J., et al. Liver transplantation recipients older than 60 years have lower survival and higher incidence of malignancy. Am J Transplant 3 11 (2003) 1407-1412
160. Saigal S., Norris S., Muiesan P., et al. Evidence of differential risk for posttransplantation malignancy based on pretransplantation cause in patients undergoing liver transplantation. Liver Transpl 8 5 (2002) 482-487
161. Jiménez C., Marqués E., Manrique A., et al. Incidence and risk factors of development of lung tumors after liver transplantation. Transplant Proc 37 9 (2005) 3970-3972
162. Duvoux C., Pageaux G.P., Vanlemmens C., et al. Risk factors for lymphoproliferative disorders after liver transplantation in adults: an analysis of 480 patients. Transplantation 74 8 (2002) 1103-1109
163. Su C.G., Stein R.B., Lewis J.D., et al. Azathioprine or 6-mercaptopurine for inflammatory bowel disease: do risks outweigh benefits?. Dig Liver Dis 32 6 (2000) 518-531
164. Duvoux C., Delacroix I., Richardet J.P., et al. Increased incidence of oropharyngeal squamous cell carcinomas after liver transplantation for alcoholic cirrhosis. Transplantation 67 3 (1999) 418-421
165. Franceschi S., Talamini R., Barra S., et al. Smoking and drinking in relation to cancers of the oral cavity, pharynx, larynx, and esophagus in Northern Italy. Cancer Res 50 20 (1990) 6502-6507
166. Castelli E., Hrelia P., Maffei F., et al. Indicators of genetic damage in alcoholics: reversibility after alcohol abstinence. Hepatogastroenterology 46 27 (1999) 1664-1668
167. Zoorob R., Anderson R., Cefalu C., et al. Cancer screening guidelines. Am Fam Physician 63 6 (2001) 1101-1112